| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Medical Sciences,
1
Clinical Chemistry and
2 Cardiology, University of Uppsala, SE-751 85 Uppsala, Sweden.
aAddress correspondence to this author at: Department of Clinical Chemistry and Pharmacology, University Hospital, SE-751 85 Uppsala, Sweden. Fax 46-186113703; e-mail per.venge{at}clm.uas.lul.se.
Background: Measurements of cardiac troponins are currently used as the standard for the detection of myocardial injury. None of the current assays complies with the new requirements on assay imprecision as proposed by the European Society of Cardiology/American College of Cardiology. Our aim was to evaluate the clinical and analytical performance of the Liaison cardiac troponin I (cTnI) assay.
Methods:EDTA-plasma was used, and cardiac troponins were assayed with the first-generation AxSYM assay, the second-generation AccuTnI assay, the third-generation Elecsys assay, and the first-generation Liaison assay.
Results: In a 6-day imprecision study, the Liaison cTnI assay had mean CV 
10% at 0.027 µg/L and 20% at 0.015 µg/L. The 99th percentile of the upper reference limit (URL) of a reference population was 0.041 µg/L (age range, 41–76 years). Individuals <60 years had a significantly (P = 0.001) lower 99th percentile, 0.022 µg/L. The FRISC-II study participants with cTnI 
0.041 µg/L had a poorer outcome relating to death/acute myocardial infarction than those with cTnI <0.041 µg/L (P <0.001). Treatment with low-molecular-weight heparin (dalteparin) or an invasive strategy reduced cardiac events only in patients with concentrations >0.041 µg/L (P = 0.002 and 0.02, respectively). Comparison with the AccuTnI assay showed that a large cohort of the patients with poor prognosis was identified by the AccuTnI assay but not by the Liaison cTnI assay.
Conclusion: The Liaison cTnI assay is a sensitive assay with a CV 10% at the 99th percentile URL. The ability to detect age-related differences among apparently healthy individuals is unique among today’s commercial assays. The results indicate that different assays seem to identify different patient cohorts for cardiac risk in the lower range of cTnI concentrations.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  H. G. Schneider, J. R. Tate, and P. E. Hickman What Criteria Should Be Used to Assess Troponin Assays? Clin. Chem., January 1, 2010; 56(1): 140 - 142. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Venge, N. Johnston, B. Lindahl, and S. James Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J. Am. Coll. Cardiol., September 22, 2009; 54(13): 1165 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Eggers, A. S. Jaffe, L. Lind, P. Venge, and B. Lindahl Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making Clin. Chem., January 1, 2009; 55(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Venge, S. James, L. Jansson, and B. Lindahl Clinical Performance of Two Highly Sensitive Cardiac Troponin I Assays Clin. Chem., January 1, 2009; 55(1): 109 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O Collinson, G. H Gaynor, and D. C Gaze Cardiac troponin I measurement using the ACS:180 to predict four-year cardiac event rate Ann Clin Biochem, March 1, 2008; 45(2): 184 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. James, M. Flodin, N. Johnston, B. Lindahl, and P. Venge The Antibody Configurations of Cardiac Troponin I Assays May Determine Their Clinical Performance Clin. Chem., May 1, 2006; 52(5): 832 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Babuin and A. S. Jaffe Troponin: the biomarker of choice for the detection of cardiac injury Can. Med. Assoc. J., November 8, 2005; 173(10): 1191 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eriksson and K. Pettersson Beliefs in Cardiac Troponin Testing Clin. Chem., September 1, 2005; 51(9): 1755 - 1756. [Full Text] [PDF]
|
|
|
|
|
|
S. Eriksson, T. Ilva, C. Becker, J. Lund, P. Porela, K. Pulkki, L.-M. Voipio-Pulkki, and K. Pettersson Comparison of Cardiac Troponin I Immunoassays Variably Affected by Circulating Autoantibodies Clin. Chem., May 1, 2005; 51(5): 848 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pagani, F. Stefini, and M. Panteghini Innotrac Aio! Second-Generation Cardiac Troponin I Assay: Imprecision Profile and Other Key Characteristics for Clinical Use Clin. Chem., July 1, 2004; 50(7): 1271 - 1272. [Full Text] [PDF]
|
|
|
|
 |
|
 K A A Fox, J Birkhead, R Wilcox, C Knight, and J Barth British Cardiac Society Working Group on the definition of myocardial infarction Heart, June 1, 2004; 90(6): 603 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Panteghini The Interfering Component in Cardiac Troponin I Immunoassays: Need for Further Experimental Evidence Clin. Chem., March 1, 2004; 50(3): 676 - 677. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
